Attovia Therapeutics, Inc. (ATTO) – What Are Researchers Thinking About This Stock?

Shares of Attovia Therapeutics, Inc. (NASDAQ:ATTO) have earned an average recommendation of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $42.20.

A number of analysts recently weighed in on the stock. Wall Street Zen raised shares of Attovia Therapeutics to a “sell” rating in a report on Saturday, September 19th. Citigroup began coverage on shares of Attovia Therapeutics in a report on Monday, August 31st. They issued a “buy” rating and a $30.00 price target for the company. Leerink Partners assumed coverage on shares of Attovia Therapeutics in a research report on Monday, August 31st. They set an “outperform” rating and a $52.00 price target for the company. Lifesci Capital started coverage on shares of Attovia Therapeutics in a report on Monday, August 31st. They issued an “outperform” rating and a $45.00 price target on the stock. Finally, Royal Bank Of Canada started coverage on Attovia Therapeutics in a research report on Monday, August 31st. They issued an “outperform” rating and a $45.00 price objective on the stock.

Attovia Therapeutics Trading Down 0.9%

NASDAQ:ATTO opened at $15.05 on Thursday. Attovia Therapeutics has a 1 year low of $12.94 and a 1 year high of $28.00. The stock’s fifty day moving average is $18.55.

Attovia Therapeutics (NASDAQ:ATTO) last released its quarterly earnings data on Wednesday, September 2nd. The company reported ($4.88) earnings per share (EPS) for the quarter. The company had revenue of $0.45 million during the quarter. On average, analysts predict that Attovia Therapeutics will post -4.06 earnings per share for the current fiscal year.

Insider Buying and Selling at Attovia Therapeutics

In other Attovia Therapeutics news, major shareholder Life Sciences Xi L.P. Frazier bought 588,235 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $9,999,995.00. Following the purchase, the insider directly owned 6,154,213 shares of the company’s stock, valued at $104,621,621. The trade was a 10.57% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Colin Walsh purchased 500,000 shares of the stock in a transaction on Thursday, August 6th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $8,500,000.00. Following the acquisition, the director owned 3,020,632 shares in the company, valued at approximately $51,350,744. This represents a 19.84% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 2,740,587 shares of company stock valued at $47,269,979 over the last 90 days.

Attovia Therapeutics Company Profile

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company focused on developing antibody-based medicines for immune-mediated and inflammatory diseases. The company is working to address conditions in which existing treatments may not provide adequate efficacy, durability, or convenience.

Attovia uses its proprietary antibody-engineering and drug-development capabilities to discover and advance biologic therapies designed to modulate disease-driving immune pathways.